Introduction: In the Phase 3 IMbrave150 trial (NCT03434379), atezolizumab + bevacizumab demonstrated a clinically meaningful survival benefit over sorafenib in patients with unresectable hepatocellula
The dataset contains information from a cohort of 799 patients admitted in the hospital for COVID-19, characterized with sociodemographic and clinical data. Retrospectively, from November 2020 to Janu